Head of Translational Cancer Nanomedicine Theme – Executive Head, Research Engagement Group Leader, Tumour Biology and Targeting at the Children’s Cancer Institute
Professor Maria Kavallaris’ proposed project to study the benefits of using nanoparticles to treat neuroblastoma was one of two major 2023 research projects awarded $175,000 in funding by Neuroblastoma Australia.
Neuroblastoma patients with recurrent and drug resistant disease have limited therapeutic options. Moreover, many of the therapies given to treat patients with recurrent and drug resistant disease are highly toxic and determined empirically, which means that children can be exposed to damaging and ineffective therapies.
Indeed, long-term survivors have a high likelihood of experiencing life-long health issues. Professor Kavallaris will bring together leading experts in childhood cancer, neuroblastoma, nanomedicine and paediatric oncology to develop effective and less toxic therapy for high-risk neuroblastoma.
This grant was partially funded through a generous donation made by the Davidson family who very sadly lost their son George in 2021 to neuroblastoma. His legacy continues as he helps other children affected by this devastating disease.
The funding from Neuroblastoma Australia will help lead to knowledge gain on the development of new strategies for neuroblastoma treatment. Therapeutic targeting coupled with advanced tumour delivery and diagnostics will lay the foundations for future clinical trials. Professor Maria Kavallaris.
Enable this content?
This content is served by a third party, www.youtube.com. If enabled, www.youtube.com may collect information about your activity. Manage preferences to always allow this content.PreferencesEnable
Published Paper
Prof. Kavallaris recently had a paper published in the Journal of Controlled Released. The paper reviews targeted nanoparticle therapeutics for neuroblastoma.
Prof. Kavallaris is continuing to build on this work and thanks Neuroblastoma Australia and has secured further funding thanks to the initial funding from Neuroblastoma Australia.
